title: Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results.
abstract: The study was aimed to investigate modifications of apoptotic gene expression profile by microarray technique in 10 patients with chronic lymphocytic leukemia by treatment with rituximab, cladribine and cyclophosphamide (RCC) according to IGHV mutational status. The TaqMan Low Density Array for 96 gene transcripts was used. Those modifications followed two distinctive patterns largely overlapping the IGHV mutational status. In the IGHV-mutated group, the expression of many proapoptotic genes increased after treatment as compared to initial value. Our results suggest that RCC drugs may act through influence on the expression of some apoptosis-involved genes dependently on the IGVH mutational status.
authors.affiliation: Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Lodz, Poland.
authors.forename: Ida
authors.initials: I
authors.lastname: Franiak-Pietryga
authors.forename: Henryk
authors.initials: H
authors.lastname: Maciejewski
authors.forename: Dariusz
authors.initials: D
authors.lastname: Wolowiec
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Salagacka
authors.forename: Jerzy Z
authors.initials: JZ
authors.lastname: Blonski
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Janus
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Kotkowska
authors.forename: Ewa
authors.initials: E
authors.lastname: Wawrzyniak
authors.forename: Paolo
authors.initials: P
authors.lastname: Ghia
authors.forename: Marek
authors.initials: M
authors.lastname: Mirowski
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Robak
authors.forename: Anna
authors.initials: A
authors.lastname: Korycka-Wolowiec
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics*; D017338:Cladribine / Q000008:administration & dosage* / Q000009:adverse effects; D016000:Cluster Analysis; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D004252:DNA Mutational Analysis; D005260:Female; D020869:Gene Expression Profiling; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D050438:Genes, Immunoglobulin Heavy Chain / Q000235:genetics; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D000069283:Rituximab; D060152:V(D)J Recombination / Q000187:drug effects / Q000235:genetics
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D017338:Cladribine; D000069283:Rituximab; D003520:Cyclophosphamide